Clinicians will likely follow the same pattern of gradual dose escalation to help patients adjust
These factors may cause elevated cortisol levels (hypercortisolism), resulting in insulin resistance, insomnia, hunger, hypertension, central adiposity and proximal muscle weakness, which contributes to accelerating diabetes, CVD and CKD progression
The data Sustained loss, month after month
Patients interested in accessing retatrutide should speak with their GP or a specialist obesity service about eligible clinical trials currently recruiting in the UK, which can be found via the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk)
Evidence of alterations in tissue carnitine transport
What does clinical research say about semaglutide's first-month effectiveness